Literature DB >> 2110071

Stimulation with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression in polycystic ovarian syndrome.

T Tanbo1, P O Dale, E Kjekshus, E Haug, T Abyholm.   

Abstract

Stimulation with human menopausal gonadotropin (hMG) or follicle-stimulating hormone (FSH) was compared in 34 patients with polycystic ovarian syndrome after pituitary gonadotrope suppression with buserelin acetate. No differences were seen in the hormone parameters observed. Also, the duration of the stimulation period and the dose of gonadotropin used were the same. In both groups a multifollicular response was seen. Oocyte retrieval and in vitro fertilization resulted in identical ratios of mature to total oocytes and cleavage rates. Nine pregnancies occurred, four in the hMG group and five in the FSH group. Of the nine pregnancies, two were the result of transfer of frozen-thawed embryos in estradiol and progesterone substituted cycles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110071     DOI: 10.1016/s0015-0282(16)53512-2

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  A randomized prospective cross-over study of highly purified follicle-stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in women aged 37-41 years.

Authors:  S Bassil; C Wyns; J Donnez
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

Review 2.  Polycystic ovarian disease (PCOD)--pregnancy rate and outcome in in vitro fertilization.

Authors:  D Bider; D Levran; S Mashiach; I Ben-Shlomo; J Dor
Journal:  J Assist Reprod Genet       Date:  1993-01       Impact factor: 3.412

Review 3.  Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment.

Authors:  Anwen Gorry; Davinia M White; Stephen Franks
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.